0
0
COPENHAGEN — A massive, 25-year registry study involving 3 million women in Denmark has revealed that certain progestogen-based hormonal contraceptives are associated with a slight increase in the risk of developing a meningioma, the most common type of primary brain tumor.
The findings, published on July 7, 2026, in JAMA Network Open, underscore that the risk is highly dependent on the specific type of birth control used, its dosage, and how it is delivered into the body. Crucially, researchers noted that this excess risk is temporary and generally fades within five years after a person stops using the contraceptive.
Unpacking the Findings: Not All Methods Carry Equal Risk
Meningiomas are slow-growing tumors that form in the membranes covering the brain and spinal cord. They account for roughly 38% to 42% of all primary central nervous system tumors in adults. While approximately 90% of them are noncancerous (benign), they can still pose serious health issues by pressing on surrounding brain tissue, leading to headaches, vision changes, or seizures.
To evaluate potential links to birth control, researchers compared 1,473 Danish women diagnosed with a meningioma against 14,717 closely matched women who did not have the tumor.
The data revealed distinct differences among contraceptive formulations:
-
Highest Association: Medroxyprogesterone acetate injections (commonly known as the birth control shot) showed the strongest statistical tie to increased risk.
-
Slightly Elevated Risk: Combined oral contraceptive pills, desogestrel-only pills, and high-dose (52 mg) levonorgestrel intrauterine devices (IUDs) also exhibited a small upward trend in risk.
-
No Elevated Risk: Lower-dose levonorgestrel IUDs did not show the same pattern, suggesting that hormone dosage plays a pivotal role.
The study also brought reassuring news: the risk was predominantly concentrated among current and recent users. After a woman discontinued the medication, the risk steadily declined over time, essentially disappearing after five years.
The Biological Clue: Why Hormones Matter
Scientists have long suspected that female sex hormones influence meningiomas, primarily because these tumors are diagnosed far more frequently in women than in men.
The biological mechanism centers on hormone receptors. Lab analyses show that many meningiomas possess progesterone receptors, meaning the tumor cells can actively respond to progesterone-like hormones (progestogens). Clinicians have historically observed that meningiomas can accelerate their growth during pregnancy—when natural progesterone levels surge—or while a patient is taking high doses of specific progestogen-based therapies, frequently shrinking once those hormone levels drop.
This new Danish study aligns closely with a landmark 2024 case-control study published in The BMJ, which similarly identified a higher meningioma risk associated with potent progestogens like medroxyprogesterone acetate, but found no such link for standard oral progesterone.
Balancing Relative Risk vs. Absolute Reality
From a global public health perspective, any safety signal regarding birth control requires careful communication. According to data from the World Health Organization (WHO), nearly 874 million women worldwide utilize contraceptive methods.
Because the baseline chance of developing a meningioma is quite small, a minor increase in “relative risk” still translates to a very low “absolute risk” for an individual. For example, if a condition affects 2 in 10,000 people, a 50% increase in relative risk only moves the needle to 3 in 10,000 people.
Independent medical experts urge the public to avoid panic. Observational registry studies like this one can identify statistical correlations, but they cannot definitively prove that the birth control directly caused the tumors.
“Registry data is incredibly powerful for spotting trends across millions of people,” explains Dr. Elena Rostova, a neuro-oncologist not involved in the study. “However, these datasets often lack granular details about a patient’s family medical history, body mass index, or smoking habits, all of which can influence overall health profiles. Patients should look at this as a tool for personalized medicine, not a reason to abruptly halt an effective contraceptive plan.”
The health risks associated with an unintended pregnancy, or the abrupt disruption of a well-tolerated medical regimen, frequently outweigh the very small absolute risk highlighted by this research.
What This Means for Patients and Consumers
For the average health-conscious consumer, the key takeaway is dialogue rather than distress. The era of viewing “birth control” as a singular, uniform category is giving way to a more nuanced understanding that different doses, delivery systems, and chemical structures behave uniquely in the human body.
If you are currently utilizing a medroxyprogesterone injection, a desogestrel-containing pill, or a higher-dose IUD, it is entirely reasonable to bring up this study at your next routine well-woman visit. Your physician can help weigh your personal medical history, family history, and lifestyle factors against the specific formulation you use.
As a general rule of thumb, anyone experiencing persistent, unusual neurological symptoms—such as chronic headaches that worsen over time, unexplained changes in vision, or seizures—should seek a comprehensive medical evaluation, regardless of their contraceptive history.
References
-
Lundstrøm, N. H., et al. (2026). Contraceptive Progestogens and Incident Meningioma. JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.22603.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
